Shares of Mednax Inc. (NYSE:MD) were up 2.9% during trading on Monday . The stock traded as high as $64.62 and last traded at $64.58, with a volume of 549,673 shares trading hands. The stock had previously closed at $62.73.

Several analysts recently commented on MD shares. Jefferies Group cut their price objective on shares of Mednax from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Friday. Robert W. Baird reaffirmed a “buy” rating on shares of Mednax in a report on Monday, May 16th. Zacks Investment Research downgraded shares of Mednax from a “buy” rating to a “hold” rating in a report on Saturday, July 30th. JPMorgan Chase & Co. dropped their price target on shares of Mednax from $85.00 to $80.00 and set an “overweight” rating on the stock in a report on Friday, July 29th. Finally, Citigroup Inc. dropped their price target on shares of Mednax from $76.00 to $72.00 and set a “neutral” rating on the stock in a report on Wednesday, August 17th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $76.11.

The firm has a 50-day moving average of $69.35 and a 200 day moving average of $68.26. The firm has a market cap of $6.01 billion and a PE ratio of 18.19.

Mednax (NYSE:MD) last announced its earnings results on Thursday, July 28th. The company reported $1.03 EPS for the quarter, missing the Zacks’ consensus estimate of $1.07 by $0.04. During the same period in the previous year, the company earned $0.90 EPS. The business had revenue of $772 million for the quarter, compared to analyst estimates of $775.68 million. The business’s quarterly revenue was up 14.1% compared to the same quarter last year. On average, equities analysts expect that Mednax Inc. will post $4.14 earnings per share for the current fiscal year.

In other news, Director Md Carlo A. Waldemar sold 5,334 shares of the business’s stock in a transaction dated Wednesday, June 8th. The stock was sold at an average price of $70.50, for a total transaction of $376,047.00. Following the sale, the director now owns 16,589 shares in the company, valued at $1,169,524.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael D. Stanley sold 14,778 shares of the business’s stock in a transaction dated Wednesday, June 1st. The stock was sold at an average price of $67.78, for a total value of $1,001,652.84. Following the sale, the insider now owns 49,266 shares in the company, valued at approximately $3,339,249.48. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Mednax stock. I.G. Investment Management LTD. raised its position in Mednax Inc. (NYSE:MD) by 5.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,823 shares of the company’s stock after buying an additional 1,743 shares during the period. I.G. Investment Management LTD.’s holdings in Mednax were worth $2,280,000 as of its most recent SEC filing.

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.